Travere Therapeutics
TVTX· Manufacturing· Fiscal year ends in December
Eric Dube, Ph.D. is the CEO of Travere Therapeutics and was paid $8.5M in FY2025 (Dec).
Executives5
See all- 1Eric Dube, Ph.D.President, Chief Executive Officer and DirectorFY2025
- 2Jula Inrig, M.D.Chief Medical OfficerFY2025
- 3Peter HeermaChief Commercial OfficerFY2025
- 4William E. Rote, Ph.D.Chief Research OfficerFY2025
- 5Christopher ClineChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTravere Therapeutics paid its 5 named executives $18.3M in total in FY2025 (Dec). CEO Eric Dube, Ph.D. was paid $8.5M of that.
| Name | |||
|---|---|---|---|
| Eric Dube, Ph.D.President, Chief Executive Officer and Director | Not disclosed | ||
| Jula Inrig, M.D.Chief Medical Officer | |||
| Peter HeermaChief Commercial Officer | Not disclosed | ||
| William E. Rote, Ph.D.Chief Research Officer | Not disclosed | ||
| Christopher ClineChief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers23
See allThe FY2025 (Dec) proxy of Travere Therapeutics names 23 peer companies for pay. Among Travere Therapeutics and these peers, CEO pay was 6th highest of 9 and total shareholder return was 5th highest of 9.
6th highest of 9in Travere Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
5th highest of 9in Travere Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Gary LyonsDirector · 11 yr on the boardIndependent—Paid as an executive
- Roy D. Baynes, M.D., Ph.D.Director · 9 yr on the boardIndependentCorporate Governance, Science and Medical Technology (Chair)—Paid as an executive
- John OrwinDirector · 8 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Suzanne Bruhn, Ph.D.Director · 5 yr on the boardIndependentCompensation, Science and Medical Technology—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 6, 2026 | FY2025 |
| Annual report | 10-K | Feb 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 1, 2025 | FY2024 |
| Annual report | 10-K | Feb 21, 2025 | FY2024 |
| Proxy statement | DEF 14A | Mar 27, 2024 | FY2023 |
| Annual report | 10-K | Feb 20, 2024 | FY2023 |